For the fiscal year ending March 2026, net sales have been upwardly revised to JPY 115.5 billion (4.5% increase from previous forecast), operating income to JPY 9.5 billion (35.7% increase), and net income attributable to owners of parent to JPY 8.4 billion (55.6% increase).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4534-20260206-02.pdf","jir_short_summary":"For the fiscal year ending March 2026, net sales have been upwardly revised to JPY 115.5 billion (4.5% increase from previous forecast), operating income to JPY 9.5 billion (35.7% increase), and net income attributable to owners of parent to JPY 8.4 billion (55.6% increase).","jir_summary":"### Overview of Revision of Earnings Guidance\nMochida Pharmaceutical Co., Ltd. has revised its consolidated earnings forecast for the fiscal year ending March 2026. Net sales are projected at JPY 115.5 billion, operating income at JPY 9.5 billion, ordinary income at JPY 11 billion, and net income attributable to owners of parent at JPY 8.4 billion, all exceeding the previously announced forecast. Net sales have been upwardly revised by 4.5%, operating income by 35.7%, ordinary income by 46.7%, and net income by 55.6% compared to the prior forecast.\n\n### Reasons for Revision and Future Outlook\nThe main reasons for the revision are steady performance in the pharmaceutical-related business and increased equity-method investment income. These factors have resulted in net sales and earnings projections exceeding the previous forecast. However, it is also noted that these forecasts are based on information available at the time of announcement and actual results may differ due to various future factors.","jir_financial_highlights":"Net Sales: 115,500 million yen (4.5% increase from previous forecast)\nOperating Income: 9,500 million yen (35.7% increase from previous forecast)\nOrdinary Income: 11,000 million yen (46.7% increase from previous forecast)\nNet Income Attributable to Owners of Parent: 8,400 million yen (55.6% increase from previous forecast)\nNet Income per Share: 236.95 yen (Unknown)","jir_category":"","jir_hashtags":"#MochidaPharmaceutical, #EarningsGuidanceRevision, #JapaneseStocks","jir_key_figures":"Net Sales: 115,500 million yen (4.5% increase from previous forecast)\nOperating Income: 9,500 million yen (35.7% increase from previous forecast)\nNet Income Attributable to Owners of Parent: 8,400 million yen (55.6% increase from previous forecast)","jir_meta_title":"Mochida Pharmaceutical Revises Fiscal Year 2026 Earnings Guidance Upward: Net Sales Up 4.5%, Net Income Up 55.6%","jir_meta_description":"Mochida Pharmaceutical Co., Ltd. has revised its consolidated earnings forecast for fiscal year ending March 2026, projecting net sales of JPY 115.5 billion, operating income of JPY 9.5 billion, and net income attributable to owners of parent of JPY 8.4 billion, significantly exceeding previous forecasts.","jir_og_title":"Mochida Pharmaceutical Revises Fiscal Year 2026 Earnings Forecast Upward","jir_og_description":"Mochida Pharmaceutical has raised its sales and profit forecasts for the fiscal year ending March 2026, supported by solid performance in its pharmaceutical business.","jir_og_image_url":"\/assets\/og\/company-earnings_guidance.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-25205","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n